When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ZLAB - MacroGenics launches mid-stage Mahogany study in gastric or gastroesophageal junction cancer
Zai Lab Limited
The first patient has been dosed in MacroGenics' (NASDAQ:MGNX) Phase 2/3 MAHOGANY clinical trial of margetuximab, a Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric or gastroesophageal junction cancer.
More news on: MacroGenics, Inc., Zai Lab Limited, Healthcare stocks news,